Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study.
Jingzhong OuyangFeng YeYanzhao ZhouXu ChangZhengzheng WangQingjun LiYu TangJianqiang CaiJinxue ZhouZhen HuangHong ZhaoPublished in: Hepatobiliary surgery and nutrition (2024)
Postoperative adjuvant camrelizumab plus apatinib significantly improved the RFS benefits with acceptable toxicities in patients with HCC with MVI.
Keyphrases